Oestrogen-induced increase in uterine cGMP content in vitro: effects of inhibitors of protein and RNA synthesis

Mol Cell Endocrinol. 1982 Jan;25(1):49-54. doi: 10.1016/0303-7207(82)90168-x.

Abstract

We have shown previously that oestradiol elevates the cGMP content od isolated uterine horns incubated for 2 h with the hormone. Cycloheximide (30 micrograms/ml) or actinomycin D (100 micrograms/ml), at concentrations which markedly inhibit protein and RNA synthesis, blocked the oestrogen-induced increase in cGMP. These agents do not inhibit the rise in uterine cGMP content provoked by sodium nitroprusside, thus arguing against a direct toxic effect on the enzyme guanylate cyclase. alpha-Amanitin, even at very high concentrations (80 micrograms/ml), interfered much less efficiently with total RNA and protein synthesis and also failed to prevent the oestrogen-induced increase in cGMP content. Taken together, these observations indicate that oestrogen action on uterine cGMP concentration in vitro depends on an RNA and/or a protein biosynthetic event that takes places in the uterus. This therefore confirms and extends analogous observations made previously under conditions in vivo.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cyclic GMP / analysis*
  • Cycloheximide / pharmacology*
  • Dactinomycin / pharmacology*
  • Estrogens / pharmacology*
  • Female
  • In Vitro Techniques
  • Nitroprusside / pharmacology
  • Protein Biosynthesis*
  • RNA / biosynthesis*
  • Rats
  • Rats, Inbred Strains
  • Uterus / analysis
  • Uterus / drug effects*

Substances

  • Estrogens
  • Nitroprusside
  • Dactinomycin
  • RNA
  • Cycloheximide
  • Cyclic GMP